1 Min Read
Jan 31 (Reuters) - BeiGene Ltd:
* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.